Last reviewed · How we verify
Administration of dornase alfa
Dornase alfa is a recombinant form of human deoxyribonuclease I that breaks down DNA in the extracellular matrix of cystic fibrosis sputum, reducing its viscosity.
Dornase alfa is a recombinant form of human deoxyribonuclease I that breaks down DNA in the extracellular matrix of cystic fibrosis sputum, reducing its viscosity. Used for Cystic fibrosis.
At a glance
| Generic name | Administration of dornase alfa |
|---|---|
| Sponsor | Fondation Ophtalmologique Adolphe de Rothschild |
| Drug class | DNase |
| Target | Deoxyribonuclease I |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
This process makes it easier to cough up mucus, improving lung function and reducing the risk of respiratory complications. Dornase alfa works by degrading DNA, which is a major component of the thick, sticky mucus produced by individuals with cystic fibrosis. By breaking down DNA, dornase alfa helps to reduce the viscosity of the mucus, making it easier to clear from the lungs.
Approved indications
- Cystic fibrosis
Common side effects
- Cough
- Sputum culture positive for Pseudomonas aeruginosa
- Hemoptysis
Key clinical trials
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- Intrapleural Alteplase-Tyloxapol vs Intrapleural Alteplase-DNase in Pleural Infection
- Pleural Irrigation With Normal Saline Versus Intrapleural Fibrinolytic (NA)
- Efficacy of Pulmozyme® on Arterial Recanalization in Post-thrombectomy Patients Managed for Ischemic Stroke (NETs-target) (PHASE2)
- VATS Surgery Compared to Drainage in the Treatment of Pleural Empyema (NA)
- Efficacy of Daily IV Administration of Dornase Alfa Up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence At 6 Months (PHASE2)
- Nebulised Dornase Alfa for Treatment of COVID-19 (Coronavirus Disease 2019) (PHASE2)
- Reduction of SystemiC Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: